Compare MXCT & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXCT | GHI |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 121.3M |
| IPO Year | 2021 | 1998 |
| Metric | MXCT | GHI |
|---|---|---|
| Price | $1.11 | $5.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.50 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 1.7M | 48.5K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 22.93% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $33,026,000.00 | ★ $85,389,766.00 |
| Revenue This Year | N/A | $273.95 |
| Revenue Next Year | $18.50 | N/A |
| P/E Ratio | ★ N/A | $486.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $4.71 |
| 52 Week High | $2.31 | $11.45 |
| Indicator | MXCT | GHI |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 42.75 |
| Support Level | $1.08 | $5.05 |
| Resistance Level | $1.16 | $5.52 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 6.10 | 30.00 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.